For anticancer drugs, ivosidenib and enasidenib were developed on the basis of oncometabolites, which inhibit mutated IDH1 [8] and mutated IDH2 [9], respectively, in acute myeloid leukemia (AML), thereby suppressing the biosynthesis of D-2-hydroxyglutarate. Here, IDH2 is linked to acute myeloid leukemia.